These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 26363365)

  • 1. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: The IGNITE study.
    Bakirtzis C; Konstantinopoulou E; Langdon DW; Grigoriadou E; Minti F; Nikolaidis I; Boziki MK; Tatsi T; Ioannidis P; Karapanayiotides T; Afrantou T; Hadjigeorgiou G; Grigoriadis N
    J Neurol Sci; 2018 Dec; 395():106-112. PubMed ID: 30308444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.
    Allart E; Benoit A; Blanchard-Dauphin A; Tiffreau V; Thevenon A; Zephir H; Outteryck O; Lacour A; Vermersch P
    J Neurol; 2015 Aug; 262(8):1936-45. PubMed ID: 26041616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
    J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
    van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
    Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD; Sørensen CB; Thorning M; Lambertsen KL; Frich LH; Jensen HB; Holsgaard-Larsen A; Nielsen HH
    Mult Scler Relat Disord; 2022 Oct; 66():104034. PubMed ID: 35843140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
    Keune PM; Cocks AJ; Young WR; Burschka JM; Hansen S; Hofstadt-van Oy U; Oschmann P; Muenssinger J
    BMC Neurol; 2015 Sep; 15():171. PubMed ID: 26400041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
    Morrow SA; Rosehart H; Johnson AM
    Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
    J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in cognition, arm function and lower body function after slow-release Fampridine treatment.
    Jensen H; Ravnborg M; Mamoei S; Dalgas U; Stenager E
    Mult Scler; 2014 Dec; 20(14):1872-80. PubMed ID: 24852920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
    J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study.
    Jensen HB; Nielsen JL; Ravnborg M; Dalgas U; Aagaard P; Stenager E
    Mult Scler Relat Disord; 2016 Nov; 10():137-144. PubMed ID: 27919481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis.
    Jensen HB; Mamoei S; Ravnborg M; Dalgas U; Stenager E
    Mult Scler Relat Disord; 2016 May; 7():58-60. PubMed ID: 27237758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
    Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
    Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.
    Yalachkov Y; Soydaş D; Bergmann J; Frisch S; Behrens M; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2019 May; 30():33-37. PubMed ID: 30735970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.